Virus News and Research

Latest Virus News and Research

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.

From Avacta Life Sciences Ltd. 8 Sep 2020

Limited gut inflammation in COVID-19

A new study by researchers at the Icahn School of Medicine at Mount Sinai and published on the preprint server medRxiv in September 2020 shows that gut infection with this virus produces primarily mucosal immunity but also a limited inflammatory response.

8 Sep 2020

Study finds strong T cell responses in patients recovered from COVID-19

Oxford University researchers have found that natural infection with COVID-19 produces a robust T cell response, including inducing T cell ‘memory’ to potentially fight future infections.

8 Sep 2020

Antibody-mediated platelet death linked to COVID-19 severity

A new study by University of Tuebingen researchers shows the strong association between platelet apoptosis and the thrombotic manifestations that may underlie critical COVID-19 illness.

7 Sep 2020

Scientists describe various dynamic structures of the SARS-CoV-2 spike protein

Early in the pandemic, scientists uncovered the role of the ACE2 receptor in SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and the angiotensin-converting enzyme 2 (ACE2) receptors act as a lock and key for cell infection.

7 Sep 2020

PI3K/mTOR and topoisomerase inhibitors suggested as candidates to reduce expression of ACE2

A recent study published in the preprint server medRxiv in September 2020 shows that the already approved drug families called P13K/mTOR and topoisomerase inhibitors may be useful in reducing individual susceptibility to the virus.

7 Sep 2020

Consortium compiles recommendations for measuring HIV reservoir size in cure-directed studies

Spearheaded by scientists at The Wistar Institute, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

7 Sep 2020

Three-year Indonesia trial produces encouraging results for dengue control

A three-year trial in Indonesia has produced encouraging results that show a significant reduction in the number of dengue cases.

7 Sep 2020

Important research on SARS-CoV-2 proteins using proximity labeling

A team of Canadian scientists has recently discovered a wide-range interaction between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and host proteins using proximity-dependent biotinylation approaches.

7 Sep 2020

Pooled saliva testing increases COVID-19 testing capacity

Now, a new study by researchers at Yale School of Medicine and published on the preprint server medRxiv in September 2020 shows that pooled saliva samples can save resources and increase testing capacity, making a significant difference in the management of the pandemic.

7 Sep 2020

Rehabilitation speeds coronavirus recovery

Now, a team of researchers at the University Clinic in Innsbruck in Austria has found that the long-term lung and heart damage in coronavirus disease (COVID-19) patients who recovered tend to improve over time.

7 Sep 2020

Using proteins to track SARS-CoV-2 infections through wastewater

A new study published on the preprint server medRxiv* in September 2020 describes the measurement of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in wastewater as a reliable way to track the virus in the community.

6 Sep 2020

Novel RNA vaccine from Arcturus Therapeutics protects mice against SARS-CoV-2

A new study published on the preprint server bioRxiv in September 2020 reports a novel RNA vaccine platform that shows robust protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice and performs much better than a conventional mRNA vaccine. This could allow single-dose immunization, allowing progress towards global vaccination.

6 Sep 2020

Seasonal influenza and COVID-19 risk

In a new study published on the preprint server medRxiv, researchers from Laval University and McGill University in Canada reviewed evidence from 18 relevant studies on a possible interaction between influenza vaccines on non-influenza respiratory disease (NIRD).

6 Sep 2020

Study shows SARS-CoV-2 cell receptor is a novel target of the gamma-secretase enzyme complex

Based on structural similarities with other targets of the gamma-secretase system, researchers from Columbia University Irving Medical Center in the United States show that the SARS-CoV-2 receptor for cell entry may be affected by its proteolytic activity. Their results are currently freely available in a bioRxiv preprint paper.

6 Sep 2020

Transparent Government builds trust and successful COVID-19 containment

The combined impact of the pandemic and these non-pharmaceutical interventions (NPIs) has taken a heavy toll on society, and this has led to much discussion as to the relative merits of these measures. A recent study published on the preprint server medRxiv in September 2020 shows that public trust is vital for the success of any such intervention.

6 Sep 2020

Monitoring the activity of unconventional T cells could predict COVID-19 severity

Researchers in France have discovered that patients suffering from severe COVID-19 show changes in a class of immune cells known as unconventional T cells.

5 Sep 2020

Early identification, treatment is vital to avoid COVID-19-related health anxieties in children

Early identification and treatment is vital to avoid long-term mental health consequences from COVID-19 among children and young people, say researchers.

5 Sep 2020

Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine

Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.

5 Sep 2020

New project to increase provision for trauma and emergency care in Zambia during COVID-19 pandemic

More than £170,000 will be used to boost trauma and emergency nursing in Zambia to help the country cope with the strain on services caused by the COVID-19 pandemic.

5 Sep 2020

Virus News and Research

Latest Virus News and Research

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

Limited gut inflammation in COVID-19

Study finds strong T cell responses in patients recovered from COVID-19

Antibody-mediated platelet death linked to COVID-19 severity

Scientists describe various dynamic structures of the SARS-CoV-2 spike protein

PI3K/mTOR and topoisomerase inhibitors suggested as candidates to reduce expression of ACE2

Consortium compiles recommendations for measuring HIV reservoir size in cure-directed studies

Three-year Indonesia trial produces encouraging results for dengue control

Important research on SARS-CoV-2 proteins using proximity labeling

Pooled saliva testing increases COVID-19 testing capacity

Rehabilitation speeds coronavirus recovery

Using proteins to track SARS-CoV-2 infections through wastewater

Novel RNA vaccine from Arcturus Therapeutics protects mice against SARS-CoV-2

Seasonal influenza and COVID-19 risk

Study shows SARS-CoV-2 cell receptor is a novel target of the gamma-secretase enzyme complex

Transparent Government builds trust and successful COVID-19 containment

Monitoring the activity of unconventional T cells could predict COVID-19 severity

Early identification, treatment is vital to avoid COVID-19-related health anxieties in children

Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine

New project to increase provision for trauma and emergency care in Zambia during COVID-19 pandemic

A new way of characterising biomolecules eBook

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Newsletters you may be interested in